TF
MYGN icon

Tompkins Financial’s Myriad Genetics MYGN Stock Holding History

Tompkins Financial’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-840
Closed -$20.5K – 611
2024
Q2 		$20.5K Hold
840
– – ﹤0.01% 432
2024
Q1 		$17.9K Hold
840
– – ﹤0.01% 445
2023
Q4 		$16.1K Buy
+840
New +$14.5K ﹤0.01% 444

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Tompkins Financial's MYGN Position: Q3 2024 in Review

Tompkins Financial sold out of Myriad Genetics (MYGN) in Q3 2024, closing a stake of 840 shares — an estimated $20.5K sold.

Tompkins Financial first reported a position in MYGN in Q4 2023 and held it in 3 quarters. The position peaked at $20.5K in Q2 2024. 246 funds tracked by Wall St. Rank hold MYGN as of Q3 2024.

  • Tompkins Financial reported no remaining Myriad Genetics position as of Q3 2024 after selling out during the quarter.
  • Tompkins Financial sold 840 Myriad Genetics shares in Q3 2024, an estimated $20.5K.
  • Tompkins Financial first reported a position in Myriad Genetics in Q4 2023 and held it in 3 quarters.
  • Tompkins Financial's Myriad Genetics position peaked at $20.5K in Q2 2024.
  • 246 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2024.

Based on Tompkins Financial's 13F filing for Q3 2024, filed 1 Nov 2024.